University of California, San Diego

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, San Diego sits in the top decile of US sponsors by registered trial count (#43 of 15,742 sponsors by registered trial count).

775 total trials 143 currently recruiting 499 completed early-phase tilt top decile by trial count

University of California, San Diego: 775 sponsored US clinical trials, 143 recruiting.

University of California, San Diego sponsors 775 registered US clinical trials on ClinicalTrials.gov, 143 of them currently recruiting, and 499 completed. 104 of these trials are in Phase 3-4 (later-stage) and 170 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Anorexia Nervosa, with 10 trials.

Top-decile sponsor footprint

University of California, San Diego ranks in the top decile of sponsors by registered trial count (#43 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 65/100

499 of 553 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

775 total, page 11 of 16

COMPLETED NA

Self-Directed Biological Transformation Initiative

NCT02241226

TERMINATED NA

Physical Activity and Education Program for Somali Women

NCT02254902

COMPLETED Phase 4

Continuous Adductor Canal Nerve Blocks: Relative Effects of a Basal Infusion v. Hourly Bolus Doses

NCT02219438

COMPLETED NA

ZIPS Study - Zip Incision aPproximation vs. Suture

NCT02213510

COMPLETED Phase 2

Comparing Buccal and Vaginal Misoprostol in Management of Early Pregnancy Loss

NCT02141555

COMPLETED NA

Physical Activity and Neuropsychological Outcomes in a Cancer Population

NCT02332876

COMPLETED NA

Improving Negative Symptoms of Psychosis In Real-world Environments

NCT02170051

COMPLETED Phase 2

Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.

NCT02634684

COMPLETED

Global Positioning System (GPS) Exposure to Environments & Relations With Biomarkers of Cancer Risk

NCT02094170

COMPLETED NA

The Neurobiology of Approach Avoidance Training in Depression

NCT02330744

COMPLETED Phase 1

Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia

NCT01555697

COMPLETED NA

Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer

NCT02454140

COMPLETED

A Complex Contraception Registry

NCT02219269

COMPLETED NA

Promoting Child Inhibitory Control Skills Around Food

NCT02077387

COMPLETED

Predictors of Exposure Success in Public Speaking Anxiety

NCT02163148

COMPLETED NA

Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)

NCT02145247

COMPLETED NA

Researching Effective Sleep Treatments (Project REST)

NCT02120989

COMPLETED NA

Prepackaged Foods to Promote Weight Loss

NCT02136290

COMPLETED

Metabolomic Profiling in Adolescents With Obesity and Diabetes

NCT02145572

COMPLETED NA

Positive Valence System Enhancement Treatment for Anxiety and Depression: Clinical Efficacy and Neural Changes

NCT02330627

COMPLETED NA

iPad as a Distraction Tool During Facial Laceration Repair

NCT02217436

COMPLETED Phase 4

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

NCT02689518

COMPLETED NA

Reproductive Health Survivorship Care Plan Pilot

NCT02176083

COMPLETED

Sentinel Lymph Node Mapping Post-Injection Site Pain

NCT02065232

COMPLETED NA

RF Surgical Sponge-Detecting System on the Function of Pacemakers and Implantable Cardioverter Defibrillators

NCT02111980

COMPLETED Early Phase 1

Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety

NCT02021214

COMPLETED Phase 2

Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity

NCT02486042

COMPLETED NA

Pre-exposure Prophylaxis Accessibility Research and Evaluation 2

NCT02125773

COMPLETED Phase 2

Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease

NCT01963845

COMPLETED NA

Effects of Epicatechin on Functional Capacity, Skeletal Muscle Structure and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction (HFPEF)

NCT02068040

COMPLETED NA

Family Based Treatment for Weight Loss With Breakfast Prescription

NCT02467036

TERMINATED Phase 2

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

NCT02043587

COMPLETED Phase 4

Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study

NCT01824082

COMPLETED NA

Nonsmokers Helping Smokers Quit

NCT02010697

COMPLETED NA

Analysis of the Effect of Antimicrobial Soap on Bacterial Survival

NCT02012348

COMPLETED Phase 4

Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response

NCT02495883

COMPLETED Phase 4

Wirelessly Observed Therapy in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis

NCT01960257

COMPLETED NA

CCTG 594: Engagement and Retention in Care for HIV+

NCT01957748

COMPLETED NA

Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental Illness

NCT02035202

COMPLETED NA

Care4Today v2.0 Application for Improving Adherence to HIV Medications

NCT02001064

COMPLETED Phase 4

Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women

NCT01958073

COMPLETED

Negative-Positive Valence Domains in Anxiety and Depression

NCT03310398

COMPLETED NA

Effects of Surfactants on the Innate Immune System

NCT01951352

COMPLETED NA

Effect of Surfactants on the Skin Microbiome

NCT01951391

COMPLETED NA

Evaluating Trauma-Informed, Evidence-Informed Interventions for Latino Families Experiencing Domestic Violence

NCT03041558

COMPLETED NA

Optimizing Sedentary Behavior Interventions to Affect Acute Physiological Changes

NCT02544867

COMPLETED Phase 1

An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema

NCT01933464

COMPLETED

Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris

NCT01929057

COMPLETED NA

CCTG 593: Testing and Linkage to Care

NCT01941121

COMPLETED NA

Treating Prediabetes in the First Trimester

NCT01926457

← Previous Page 11 of 16 Next →

Phase Distribution

PhaseTrial count
Phase 1 80
Phase 2 90
Phase 3 22
Phase 4 82

What is open in the University of California, San Diego pipeline

143 recruiting of 775 indexed (18% open); 499 completed (64%).

Phase mix: 104 late (III/IV) vs 170 early (I/II) (early-phase heavy).

Top condition: Anorexia Nervosa (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, San Diego: open-pipeline peers nationwide

Peers matched on 775 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

University of California, San Diego sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share University of California, San DiegoDana-Farber Cancer InstituteMedical University of South CarolinaUniversity of ChicagoUniversity of UtahNeurocrine BiosciencesThomas Jefferson UniversityAbramson Cancer Center at Penn MedicineUniversity of Maryland, Baltimore
University of California, San Diego sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, San Diego sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 775 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this University of California, San Diego page

775 registered trials is a research-attention snapshot, not an endorsement of University of California, San Diego or any single study.

  • 143 of University of California, San Diego's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Anorexia Nervosa is the condition University of California, San Diego studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Anorexia Nervosa trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Diego pipeline card: 775 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.